FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159486180> ?p ?o ?g. }

• W3159486180 endingPage "1288" @default.
• W3159486180 startingPage "1283" @default.
• W3159486180 abstract "Objective Anti-beta 2 glycoprotein I IgA is a common isotype of anti-beta 2 glycoprotein I in SLE. Anti-beta 2 glycoprotein I was not included in the American College of Rheumatology (ACR) SLE classification criteria, but was included in the Systemic Lupus International Collaborating Clinics (SLICC) criteria. We aimed to evaluate the prevalence of anti-beta 2-glycoprotein I IgA in SLE versus other rheumatic diseases. In addition, we examined the association between anti-beta 2 glycoprotein I IgA and disease manifestations in SLE. Methods The dataset consisted of 1384 patients, 657 with a consensus physician diagnosis of SLE and 727 controls with other rheumatic diseases. Anti-beta 2 glycoprotein I isotypes were measured by ELISA. Patients with a consensus diagnosis of SLE were compared to controls with respect to presence of anti-beta 2 glycoprotein I. Among patients with SLE, we assessed the association between anti-beta 2 glycoprotein I IgA and clinical manifestations. Results The prevalence of anti-beta 2 glycoprotein I IgA was 14% in SLE patients and 7% in rheumatic disease controls (odds ratio, OR 2.3, 95% CI: 1.6, 3.3). It was more common in SLE patients who were younger patients and of African descent (p = 0.019). Eleven percent of SLE patients had anti-beta 2 glycoprotein I IgA alone (no anti-beta 2 glycoprotein I IgG or IgM). There was a significant association between anti-beta 2 glycoprotein I IgA and anti-dsDNA (p = 0.001) and the other antiphospholipid antibodies (p = 0.0004). There was no significant correlation of anti-beta 2 glycoprotein I IgA with any of the other ACR or SLICC clinical criteria for SLE. Those with anti-beta 2 glycoprotein I IgA tended to have a history of thrombosis (12% vs 6%, p = 0.071), but the difference was not statistically significant. Conclusion We found the anti-beta 2 glycoprotein I IgA isotype to be more common in patients with SLE and in particular, with African descent. It could occur alone without other isotypes." @default.
• W3159486180 created "2021-05-10" @default.
• W3159486180 creator A5007456682 @default.
• W3159486180 creator A5010072602 @default.
• W3159486180 creator A5010374020 @default.
• W3159486180 creator A5011252269 @default.
• W3159486180 creator A5015627032 @default.
• W3159486180 creator A5015927371 @default.
• W3159486180 creator A5018447862 @default.
• W3159486180 creator A5021381077 @default.
• W3159486180 creator A5023265561 @default.
• W3159486180 creator A5024237017 @default.
• W3159486180 creator A5024449200 @default.
• W3159486180 creator A5027057428 @default.
• W3159486180 creator A5028370367 @default.
• W3159486180 creator A5029793095 @default.
• W3159486180 creator A5032896722 @default.
• W3159486180 creator A5036050193 @default.
• W3159486180 creator A5039454860 @default.
• W3159486180 creator A5041627206 @default.
• W3159486180 creator A5041711237 @default.
• W3159486180 creator A5042283831 @default.
• W3159486180 creator A5043181396 @default.
• W3159486180 creator A5043615700 @default.
• W3159486180 creator A5049489990 @default.
• W3159486180 creator A5052053321 @default.
• W3159486180 creator A5052911433 @default.
• W3159486180 creator A5056786735 @default.
• W3159486180 creator A5058020714 @default.
• W3159486180 creator A5062506424 @default.
• W3159486180 creator A5065798696 @default.
• W3159486180 creator A5069100301 @default.
• W3159486180 creator A5071079442 @default.
• W3159486180 creator A5071430304 @default.
• W3159486180 creator A5072473587 @default.
• W3159486180 creator A5079843231 @default.
• W3159486180 creator A5082713013 @default.
• W3159486180 creator A5082825997 @default.
• W3159486180 creator A5085769049 @default.
• W3159486180 creator A5086170092 @default.
• W3159486180 creator A5086180632 @default.
• W3159486180 creator A5087623308 @default.
• W3159486180 creator A5088742413 @default.
• W3159486180 date "2021-05-06" @default.
• W3159486180 modified "2023-10-15" @default.
• W3159486180 title "Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset" @default.
• W3159486180 cites W1831488443 @default.
• W3159486180 cites W1837874984 @default.
• W3159486180 cites W1972437914 @default.
• W3159486180 cites W1973782940 @default.
• W3159486180 cites W2015878170 @default.
• W3159486180 cites W2037123060 @default.
• W3159486180 cites W2046670919 @default.
• W3159486180 cites W2047184949 @default.
• W3159486180 cites W2054330426 @default.
• W3159486180 cites W2066133643 @default.
• W3159486180 cites W2074991275 @default.
• W3159486180 cites W2080268645 @default.
• W3159486180 cites W2146203649 @default.
• W3159486180 cites W2159860161 @default.
• W3159486180 cites W2398112451 @default.
• W3159486180 cites W2414652162 @default.
• W3159486180 cites W2471124590 @default.
• W3159486180 doi "https://doi.org/10.1177/09612033211014248" @default.
• W3159486180 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33957797" @default.
• W3159486180 hasPublicationYear "2021" @default.
• W3159486180 type Work @default.
• W3159486180 sameAs 3159486180 @default.
• W3159486180 citedByCount "3" @default.
• W3159486180 countsByYear W31594861802021 @default.
• W3159486180 countsByYear W31594861802022 @default.
• W3159486180 countsByYear W31594861802023 @default.
• W3159486180 crossrefType "journal-article" @default.
• W3159486180 hasAuthorship W3159486180A5007456682 @default.
• W3159486180 hasAuthorship W3159486180A5010072602 @default.
• W3159486180 hasAuthorship W3159486180A5010374020 @default.
• W3159486180 hasAuthorship W3159486180A5011252269 @default.
• W3159486180 hasAuthorship W3159486180A5015627032 @default.
• W3159486180 hasAuthorship W3159486180A5015927371 @default.
• W3159486180 hasAuthorship W3159486180A5018447862 @default.
• W3159486180 hasAuthorship W3159486180A5021381077 @default.
• W3159486180 hasAuthorship W3159486180A5023265561 @default.
• W3159486180 hasAuthorship W3159486180A5024237017 @default.
• W3159486180 hasAuthorship W3159486180A5024449200 @default.
• W3159486180 hasAuthorship W3159486180A5027057428 @default.
• W3159486180 hasAuthorship W3159486180A5028370367 @default.
• W3159486180 hasAuthorship W3159486180A5029793095 @default.
• W3159486180 hasAuthorship W3159486180A5032896722 @default.
• W3159486180 hasAuthorship W3159486180A5036050193 @default.
• W3159486180 hasAuthorship W3159486180A5039454860 @default.
• W3159486180 hasAuthorship W3159486180A5041627206 @default.
• W3159486180 hasAuthorship W3159486180A5041711237 @default.
• W3159486180 hasAuthorship W3159486180A5042283831 @default.
• W3159486180 hasAuthorship W3159486180A5043181396 @default.
• W3159486180 hasAuthorship W3159486180A5043615700 @default.
• W3159486180 hasAuthorship W3159486180A5049489990 @default.
• W3159486180 hasAuthorship W3159486180A5052053321 @default.
• W3159486180 hasAuthorship W3159486180A5052911433 @default.

• next